These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 24812044)
41. NICE and drugs for multiple sclerosis. National Institute of Clinical Excellence. Hartung HP Lancet; 2000 Sep; 356(9235):1114. PubMed ID: 11009171 [No Abstract] [Full Text] [Related]
42. [Disease modifying drugs in multiple sclerosis and pregnancy]. Tur C; Tintoré M; Aguilera C Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277 [No Abstract] [Full Text] [Related]
43. Benign multiple sclerosis: a distinct clinical entity with therapeutic implications. Pittock SJ; Rodriguez M Curr Top Microbiol Immunol; 2008; 318():1-17. PubMed ID: 18219812 [TBL] [Abstract][Full Text] [Related]
44. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA; Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268 [TBL] [Abstract][Full Text] [Related]
45. A 29-year-old man with multiple sclerosis. Rudick RA JAMA; 1998 Oct; 280(16):1432-9. PubMed ID: 9801004 [No Abstract] [Full Text] [Related]
46. Options for multiple sclerosis therapy. Cotton P JAMA; 1994 Nov; 272(18):1393. PubMed ID: 7933404 [No Abstract] [Full Text] [Related]
47. More immunotherapy for multiple sclerosis. Hughes RA; Sharrack B J Neurol Neurosurg Psychiatry; 1996 Sep; 61(3):239-41. PubMed ID: 8795592 [No Abstract] [Full Text] [Related]
49. Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study. Saiz A; Mora S; Blanco J; Neurologia; 2015 May; 30(4):214-22. PubMed ID: 24484756 [TBL] [Abstract][Full Text] [Related]
50. Current and future role of interferon beta in the therapy of multiple sclerosis. Farrell RA; Giovannoni G J Interferon Cytokine Res; 2010 Oct; 30(10):715-26. PubMed ID: 20874249 [TBL] [Abstract][Full Text] [Related]
51. [Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis]. Tsareva EY; Favorova OO; Boyko AN; Kulakova OG Mol Biol (Mosk); 2019; 53(4):574-599. PubMed ID: 31397433 [TBL] [Abstract][Full Text] [Related]
52. Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis. Neumann H; Csepregi A; Sailer M; Malfertheiner P J Neurol; 2007 Jun; 254(6):816-7. PubMed ID: 17351724 [No Abstract] [Full Text] [Related]